Timothy M. Mayleben - 17 Jun 2022 Form 4 Insider Report for Landos Biopharma, Inc.

Role
Director
Signature
/s/ Eric W. Blanchard, Attorney-in-Fact
Issuer symbol
N/A
Transactions as of
17 Jun 2022
Net transactions value
$0
Form type
4
Filing time
22 Jun 2022, 16:29:23 UTC
Previous filing
07 Feb 2022
Next filing
30 Jan 2023
SEC
View on sec.gov

Derivative Securities (e.g., puts, calls, warrants, options, convertible securities)

Type Sym Class Transaction Value $ Shares Change % * Price $ Shares After Date Underlying Class Amount Exercise Price Ownership Footnotes
transaction LABP Stock Option (right to buy) Award $0 +18,000 $0.000000 18,000 17 Jun 2022 Common Stock 18,000 $0.7900 Direct F1
* An asterisk sign (*) next to the price indicates that the price is likely invalid.

Explanation of Responses:

Id Content
F1 The shares subject to this option will vest and become exercisable on June 7, 2023, subject to the Reporting Person providing continuous service through such date.